UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 3,200 shares, a growth of 166.7% from the April 30th total of 1,200 shares. Based on an average daily volume of 158,300 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

UCB Trading Up 2.8%

UCBJY stock traded up $2.48 during midday trading on Friday, hitting $90.77. 33,333 shares of the company traded hands, compared to its average volume of 47,824. UCB has a twelve month low of $68.25 and a twelve month high of $106.60. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business has a 50 day simple moving average of $85.79 and a 200-day simple moving average of $93.14.

UCB Increases Dividend

The company also recently disclosed a dividend, which was paid on Wednesday, May 14th. Investors of record on Tuesday, April 29th were issued a dividend of $0.4838 per share. This is an increase from UCB's previous dividend of $0.46. This represents a dividend yield of 0.62%. The ex-dividend date of this dividend was Monday, April 28th.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.